Frontlight ResearchEarly access
Myasthenia gravis trials in Austria
3 of 5 trials · From ClinicalTrials.gov, checked 16 November 2026. Ask the study team whether a trial fits you.
- Phase 2/3CompletedEvaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis
- Where
- Vienna
- Age
- 2 years to 18 years
- People
- 12 worldwide
- Run by
- argenx
See details and how to joinNCT05374590 · EU 2023-507379-23-00 - Phase 3Not yet taking people in AustriaComparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
- Where
- Vienna
- Age
- 18 years to 74 years
- People
- 115 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07217587 · EU 2025-521130-28-00 - Phase 3Not yet taking people in AustriaA Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)
- Where
- Linz, Salzburg, Schwarzach Im Pongau, Wels
- Age
- 18 years to 80 years
- People
- 195 worldwide
- Run by
- Dianthus Therapeutics
See details and how to joinNCT07647510 · EU 2026-525298-38-00